8-K 1 y19918e8vk.htm FORM 8-K 8-K
Table of Contents

 
 
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
April 17, 2006
 
Date of Report (Date of earliest event reported)
OSI PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
         
Delaware   0-15190   13-3159796
         
(State or other jurisdiction of   (Commission   (I.R.S. Employer
incorporation)   File Number)   Identification No.)
41 Pinelawn Road
           Melville, NY 11747           
(Address of principal executive offices)
           (631) 962-2000           
(Registrant’s telephone number, including area code)
           N/A           
(Former name or former address,
if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a- 12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

TABLE OF CONTENTS

ITEM 8.01. Other Events
ITEM 9.01. Financial Statements and Exhibits
SIGNATURE
EXHIBIT INDEX
EX-99.1: PRESS RELEASE

Table of Contents

ITEM 8.01. Other Events.
     On April 17, 2006, OSI Pharmaceuticals, Inc. (“OSI”) announced that a new drug application had been submitted in Japan for the use of Tarcevaâ (erlotinib) for the treatment of advanced or recurrent non-small cell lung cancer. A copy of OSI’s press release, dated April 17, 2006, is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
ITEM 9.01. Financial Statements and Exhibits.
     
Exhibit No.   Description
 
    
99.1
  Press release, dated April 17, 2006.

 

Table of Contents

SIGNATURE
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
                     
Date: April 18, 2006   OSI PHARMACEUTICALS, INC.    
 
                    
 
      By:   /s/  Barbara A. Wood    
                 
            Name: Barbara A. Wood    
 
          Title:   Vice President, General    
 
              Counsel and Secretary    

 

Table of Contents

EXHIBIT INDEX
     
Exhibit No.   Description
 
    
99.1
  Press release, dated April 17, 2006.

-2-